On the above 2-week chart uniQure N.V. price action has corrected 90% without the aid of share splits. A number of reasons now exist to consider a long position. They include:
1) Price action returns to legacy support.
2) RSI resistance breakout.
3) Strong positive divergence as measured over a 2-month period. Look left.
4) No share splits.
5) Price action...
Entry Price: $18.90
Stop Loss: $13.00
Take Profit: $25-$30 (=25% to +50%)
Technical Analysis
- Oversold on daily and weekly charts - low RSI and William %R
- Attempting a breakout above key MA's on the daily and retracing on the weekly.
- Formed a wedge/consolidated on the daily chart
- Key breakout on daily and weekly DMI
- Buy zone of $17-$20
- Target...
Bullish
Fundamental
- High inflationary Macro environment / Market has no fear sentiment
- Funds Accumulation
- Positive PE
- Decent PEG
- Positive P/FCF
- Strong Sector / Industry
- Biotech seems to be breaking out
Technical
- Momentum Theory Indicator - bottomed and broke out neckline
- Price action formation ( falling wedge )
- Broke out Trend line...
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands
its a late post but just want to see how this end up.
i kept an eye on the re-test..
and placed an order at $18.45 after the re-test lets see where this is going.
Hello and welcome to another breakdown of a hot stockpick i've come across with the ticker symbol $QURE. Enjoy and please remember to share!
*this is not investment advice, invest at your own risk*
uniQure NV is a gene therapy company. It develops treatment and platform for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol...
QURE should continue climbing with recent sell off from news wall street did not like regarding licensing of their hemophilia drug. Support on Weekly MA found, MACD cross and RSI bullish divergence.
Phase 3 results should likely come out sometime in the future, like this quarter(?), based on company's prior reports.
Long-term consolidation has been broken down. The company's financial performance leaves much to be desired. The target levels of the downtrend can be the long-term support levels of 21.85, 4.70.
